Asset Details
Do you wish to reserve the book?
Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19
Do you wish to request the book?
Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19
2020
Overview
To assess efficacy and safety of chloroquine (CQ)/hydroxychloroquine (HCQ) for treatment or prophylaxis of COVID-19 in adult humans.
MEDLINE, PubMed, EMBASE and two pre-print repositories (bioRxiv, medRxiv) were searched from inception to 8th June 2020 for RCTs and nonrandomized studies (retrospective and prospective, including single-arm, studies) addressing the use of CQ/HCQ in any dose or combination for COVID-19.
Thirty-two studies were included (6 RCTs, 26 nonrandomized, 29,192 participants). Two RCTs had high risk, two ‘some concerns’ and two low risk of bias (Rob2). Among nonrandomized studies with comparators, nine had high risk and five moderate risk of bias (ROBINS-I). Data synthesis was not possible. Low and moderate risk of bias studies suggest that treatment of hospitalized COVID-19 with CQ/HCQ may not reduce risk of death, compared to standard care. High dose regimens or combination with macrolides may be associated with harm. Postexposure prophylaxis may not reduce the rate of infection but the quality of the evidence is low.
Patients with COVID-19 should be treated with CQ/HCQ only if monitored and within the context of high quality RCTs. High quality data about efficacy/safety are urgently needed.
•As of June 2020 there is no high quality evidence regarding hydroxychloroquine (HCQ) as treatment or prophylaxis of COVID-19.•Treatment with HCQ may be associated with no reduction of in-hospital death compared to standard care.•High dosages, comorbidities and combinations with macrolides may increase the risk of death and cardiac adverse events.•Post-exposure prophylaxis with HCQ probably has no effect on preventing COVID-19-like symptoms.•HCQ should not be used outside high-quality RCTs in patients with COVID-19.
Publisher
Elsevier Inc,Elsevier Limited
Subject
/ Antiviral Agents - therapeutic use
/ Bias
/ Chloroquine - therapeutic use
/ Coronavirus Infections - drug therapy
/ Coronavirus Infections - prevention & control
/ COVID-19
/ Drugs
/ Humans
/ Hydroxychloroquine - therapeutic use
/ Pandemics - prevention & control
/ Pneumonia, Viral - drug therapy
/ Pneumonia, Viral - prevention & control
